

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability								
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Set of samples 1															
(81) Digoxin					128										
Samples and groups		[nmol/L]													
Sample A1		1,40	0,23	17	128										
(1) FIA, FPIA, DELFIA		1,48	0,11	7,8	6	0			CRV	1,403	0,014	36%	0,897	1,91	128 125 98%
(2) EIA (EMIT, CEDIA)		1,30	0,21	16	7	0									6
(4) LIA, ILMA		1,36	0,26	19	71	0									7
(6) Immunoturbidimetry		1,46	0,16	11	44	0									71
Sample B1		3,54	0,39	11	128										44
(1) FIA, FPIA, DELFIA		3,60	0,15	4,1	6	0			CRV	3,551	0,036	36%	2,27	4,83	128 128 100%
(2) EIA (EMIT, CEDIA)		3,43	0,52	15	7	0									6
(4) LIA, ILMA		3,47	0,45	13	71	0									7
(6) Immunoturbidimetry		3,67	0,24	6,5	44	0									71
(82) Theophylline					87										44
Samples and groups		[µmol/L]													
Sample A1		51,6	3,2	6,3	87										
(1) FIA, FPIA, DELFIA		53,8	2,6	4,8	15	0			CRV	52,12	0,52	24%	39,6	64,7	87 87 100%
(2) EIA (EMIT, CEDIA)		48,4	1,8	3,7	6	0									15
(4) LIA, ILMA		51,4	3,5	6,8	39	0									6
(6) Immunoturbidimetry		51,1	2,5	5,0	27	0									39
Sample B1		65,3	4,2	6,4	87										27
(1) FIA, FPIA, DELFIA		67,7	2,8	4,1	15	0			CRV	66,17	0,66	24%	50,2	82,1	87 87 100%
(2) EIA (EMIT, CEDIA)		62,9	4,2	6,7	6	0									15
(4) LIA, ILMA		65,3	5,4	8,2	39	0									6
(6) Immunoturbidimetry		64,9	3,3	5,0	27	0									39
(83) Primidone					9										27
Samples and groups		[µmol/L]													
Sample A1		30,0	1,1	3,6	9										
(3) HPLC, GC		30,0	1,1	3,6	5	0	CVP	30	1,3	24%	22,8	37,2			9 9 100%
Other					4	0									5
															4
Sample B1		35,1	1,3	3,6	9										
(3) HPLC, GC		35,3	0,49	1,4	5	0	CVP	35,1	1,6	24%	26,6	43,6			9 9 100%
Other					4	0									5
															4
(84) Phenobarbital					27										
Samples and groups		[µmol/L]													
Sample A1		57,0	4,8	8,4	27										
(1) FIA, FPIA, DELFIA		56,6	2,1	3,6	6	0	CVP	57	2,2	20%	45,6	68,4			27 26 96%
															6

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(84) Phenobarbital					27							27	26	96%									0
Samples and groups	[µmol/L]																						
Sample A1		57,0	4,8	8,4	27	CVP	57	2,2	20%	45,6	68,4	27	26	96%									0
(4) LIA, ILMA		59,6	4,4	7,3	12							12											
(6) Immunoturbidimetry		52,0	5,5	11	5							5											
Other					4							4											
							1x 2, 2x 3, 1x 5																
Sample B1		160	11	6,8	27	CVP	160	5,2	20%	128	192	27	27	100%									0
(1) FIA, FPIA, DELFIA		152	4,6	3,0	6							6											
(4) LIA, ILMA		167	9,9	5,9	12							12											
(6) Immunoturbidimetry		156	9,2	5,9	5							5											
Other					4							4											
							1x 2, 2x 3, 1x 5																
(85) Phenytoin					48							48	47	98%									0
Samples and groups	[µmol/L]																						
Sample A1		50,8	3,1	6,1	48	CVP	50,8	1,1	20%	40,6	61	48	47	98%									0
(1) FIA, FPIA, DELFIA		51,0	2,4	4,8	9							9											
(4) LIA, ILMA		51,4	4,2	8,1	21							21											
(6) Immunoturbidimetry		49,1	1,7	3,4	11							11											
Other					7							7											
							2x 2, 4x 3, 1x 5																
Sample B1		61,4	3,6	5,9	48	CVP	61,4	1,3	20%	49,1	73,7	48	48	100%									0
(1) FIA, FPIA, DELFIA		62,6	3,1	5,0	9							9											
(4) LIA, ILMA		61,7	4,1	6,7	21							21											
(6) Immunoturbidimetry		60,1	2,2	3,7	11							11											
Other					7							7											
							2x 2, 4x 3, 1x 5																
(86) Carbamazepin					64							64	61	95%									0
Samples and groups	[µmol/L]																						
Sample A1		23,8	2,1	8,6	64	CVP	23,8	0,63	20%	19	28,6	64	61	95%									0
(1) FIA, FPIA, DELFIA		24,6	0,42	1,7	9							9											
(2) EIA (EMIT, CEDIA)		23,7	5,0	21	8							8											
(4) LIA, ILMA		23,8	1,4	5,8	28							28											
(6) Immunoturbidimetry		22,9	2,3	10	14							14											
Other					5							5											
							4x 3, 1x 5																
Sample B1		17,2	1,7	9,8	64	CVP	17,2	0,51	20%	13,7	20,7	64	62	97%									0
(1) FIA, FPIA, DELFIA		17,5	0,71	4,1	9							9											
(2) EIA (EMIT, CEDIA)		17,3	4,4	25	8							8											
(4) LIA, ILMA		17,2	1,1	6,4	28							28											
(6) Immunoturbidimetry		16,6	2,1	13	14							14											
Other					5							5											
							4x 3, 1x 5																
(87) Ethosuximide					8							8	7	88%									0
Samples and groups	[µmol/L]																						
Sample A1		458	31	6,8	8	CVP	458	24	24%	348	568	8	7	88%									0
Other					8							8											
							1x 2, 4x 3, 3x 5																
Sample B1		482	24	4,9	8	CVP	482	18	24%	366	598	8	8	100%									0

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(87) Ethosuximide					8							8	7	88%									0
Samples and groups	[µmol/L]																						
Sample B1		482	24	4,9	8		CVP	482	18	24%	366	598	8	8	100%								0
Other					8	0							8										
							1x 2, 4x 3, 3x 5																
(88) Valproic acid					84								84	82	98%								0
Samples and groups	[µmol/L]																						
Sample A1		519	32	6,1	84		CVP	519	8,5	20%	415	623	84	83	99%								0
(1) FIA, FPIA, DELFIA		508	16	3,2	17	0							17										
(2) EIA (EMIT, CEDIA)		540	33	6,1	16	0							16										
(4) LIA, ILMA		509	33	6,5	37	0							37										
(6) Immunoturbidimetry		542	36	6,7	14	0							14										
Sample B1		239	17	7,2	84		CVP	239	4,6	20%	191	287	84	83	99%								0
(1) FIA, FPIA, DELFIA		237	7,3	3,1	17	0							17										
(2) EIA (EMIT, CEDIA)		251	15	6,1	16	0							16										
(4) LIA, ILMA		231	14	6,1	37	0							37										
(6) Immunoturbidimetry		251	18	7,1	14	0							14										
Set of samples 2																							
(89) Amicacin					30								30	25	83%								0
Samples and groups	[µmol/L]																						
Sample A2		6,42	0,92	14	30		CVP	6,42	0,41	20%	5,13	7,71	30	25	83%								0
(1) FIA, FPIA, DELFIA		6,48	0,67	10	9	0							9										
(6) Immunoturbidimetry		6,22	0,80	13	18	0							18										
Other					3	0							3										
							3x 2																
Sample B2		22,4	1,2	5,4	30		CVP	22,4	0,54	20%	17,9	26,9	30	28	93%								0
(1) FIA, FPIA, DELFIA		23,0	0,44	1,9	9	0							9										
(6) Immunoturbidimetry		22,1	1,2	5,5	18	0							18										
Other					3	0							3										
							3x 2																
(90) Gentamicin					59								59	54	92%								0
Samples and groups	[µmol/L]																						
Sample A2		28,3	5,2	18	59		CVP	28,3	1,7	31%	19,5	37,1	59	54	92%								0
(1) FIA, FPIA, DELFIA		27,4	4,5	16	13	0							13										
(4) LIA, ILMA		29,5	3,0	10	24	0							24										
(6) Immunoturbidimetry		26,9	7,1	27	18	0							18										
Other					4	0							4										
							4x 2																
Sample B2		13,6	1,6	12	59		CVP	13,6	0,51	31%	9,38	17,9	59	59	100%								0
(1) FIA, FPIA, DELFIA		13,1	0,66	5,0	13	0							13										
(4) LIA, ILMA		14,6	1,2	8,1	24	0							24										
(6) Immunoturbidimetry		12,9	2,2	17	18	0							18										
Other					4	0							4										
							4x 2																

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(92) Vancomycin					61							61	60	98%									0
Samples and groups	[µmol/L]																						
Sample A2		31,4	3,5	11	61	CVP	31,4	1,1	28%	22,6	40,2	61	60	98%									0
(1) FIA, FPIA, DELFIA		36,5	2,2	6,1	14							14											
(4) LIA, ILMA		30,0	2,9	9,8	30							30											
(6) Immunoturbidimetry		30,8	1,6	5,2	13							13											
Other					4							4											
Sample B2		21,8	2,6	12	61	CVP	21,8	0,82	28%	15,6	28	61	60	98%									0
(1) FIA, FPIA, DELFIA		25,3	1,9	7,4	14							14											
(4) LIA, ILMA		20,7	1,9	9,2	30							30											
(6) Immunoturbidimetry		21,8	1,5	6,7	13							13											
Other					4							4											
(93) Methotrexate					12							12	9	75%									0
Samples and groups	[µmol/L]																						
Sample A2		0,568	0,06	12	12	CVP	0,568	0,049	30%	0,397	0,739	12	10	83%									0
(4) LIA, ILMA		0,570	0,03	5,2	8							8											
Other					4							4											
Sample B2		1,72	0,40	24	12	CVP	1,72	0,29	30%	1,2	2,24	12	9	75%									0
(4) LIA, ILMA		1,85	0,24	13	8							8											
Other					4							4											

st_kn_np

End of report

Printed: 18.04.2019